Page last updated: 2024-12-06
flucythrinate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 50980 |
| CHEMBL ID | 2289397 |
| SCHEMBL ID | 682196 |
| MeSH ID | M0090493 |
Synonyms (54)
| Synonym |
|---|
| AC-12669 |
| epa pesticide chemical code 118301 |
| benzeneacetic acid, 4-(difluoromethoxy)-alpha-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester |
| hsdb 6647 |
| cyano(3-phenoxyphenyl)methyl 2-(4-(difluoromethoxy)phenyl)-3-methylbutyrate |
| 4-(difluoromethoxy)-alpha-(1-methylethyl)benzeneacetic acid cyano(3-phenoxy-phenyl)methyl ester |
| cythrin |
| flucythrinate [ansi:bsi:iso] |
| ac 222705 |
| caswell no. 002aa |
| (+-)-alpha-cyano-m-phenoxy-benzyl (+)-2-(p-difluoromethoxy)phenyl-3-methylbutyrate |
| (rs)-alpha-cyano-3-phenoxybenzyl (s)-2-(4-difluoromethoxyphenyl)-3-methylbutyrate |
| (+-)-cyano(3-phenoxyphenyl)methyl (+)-(4-difluoromethoxy)-alpha-(1-methylethyl)benzeneacetate |
| fluorocythrin |
| stock guard |
| cybolt |
| cyano(3-phenoxyphenyl)methyl 4-(difluoromethoxy)-alpha-(1-methylethyl)benzeneac |
| (+-)-cyano-(3-phenoxyphenyl)methyl (+)-4-(difluoromethoxy)-alpha-(methylethyl)benzeneacetate |
| (rs)-cyano-(3-phenoxyphenyl)methyl (s)-4-(difluoromethoxy)-alpha-(1-methylethyl)benzeneacetate |
| (+-)-cyano(3-phenoxyphenyl)methyl(+)-4-(difluoromethoxy)-alpha-(1-methylethyl)benzeneacetate |
| funchiong jujr |
| einecs 274-322-7 |
| pay off |
| pay-off |
| brn 2195795 |
| flucythrinate |
| 70124-77-5 |
| unii-57d0gao3rx |
| 57d0gao3rx , |
| dtxsid0022301 , |
| [cyano-(3-phenoxyphenyl)methyl] 2-[4-(difluoromethoxy)phenyl]-3-methyl-butanoate |
| FT-0630796 |
| AKOS015902545 |
| alpha-cyano-3-phenoxybenzyl 4-difluoromethoxy-alpha-isopropylphenylacetate |
| CHEMBL2289397 |
| SCHEMBL682196 |
| flucythrinate [hsdb] |
| (+/-)-cyano-(3-phenoxyphenyl)methyl (+)-4-(difluoromethoxy)-.alpha.-(1-methylethyl)benzeneacetate |
| flucythrinate [mi] |
| cyano(3-phenoxyphenyl)methyl 2-(4-(difluoromethoxy)phenyl)-3-methylbutanoate |
| benzeneacetic acid, 4-(difluoromethoxy)-.alpha.-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester |
| flucythrinate [iso] |
| (rs)-cyano-(3-phenoxyphenyl)methyl (s)-4-(difluoromethoxy)-.alpha.-(1-methylethyl)benzeneacetate |
| 4-(difluoromethoxy)-a-(1-methylethyl)benzeneacetic acid cyano(3-phenoxyphenyl)methyl ester |
| alpha-cyano-m-phenoxybenzyl alpha-isopropyl-4-difluoromethoxyphenylacetate |
| (+)-alpha-cyano-m-phenoxybenzyl (+)-alpha-isopropyl-4-difluoromethoxyphenylacetate |
| cyano(3-phenoxyphenyl)methyl 2-[4-(difluoromethoxy)phenyl]-3-methylbutanoate # |
| flucythrinate, pestanal(r), analytical standard |
| flucythrinate 100 microg/ml in isooctane |
| flucythrinate 10 microg/ml in cyclohexane |
| Q1430580 |
| fluorocythrin; pay-offv;ac 222705; cybolt |
| [(s)-cyano-(3-phenoxyphenyl)methyl] 2-[4-(difluoromethoxy)phenyl]-3-methylbutanoate |
| flucythrinate 1000 microg/ml in acetone |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Male Sprague-Dawley rats dosed with N-nitrosodiethylamine (NDEA) 24 h after two-thirds partial hepatectomy were treated with the pyrethroid insecticides fenvalerate, flucythrinate or cypermethrin in the diet for 20 weeks." | ( Enhancement of altered hepatic foci in rat liver and inhibition of intercellular communication in vitro by the pyrethroid insecticides fenvalerate, flucythrinate and cypermethrin. Flodström, S; Hemming, H; Wärngård, L, 1993) | 0.68 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (17)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 12 (70.59) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 24.45
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.45) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (5.56%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (94.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||